GSK

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

GSK
Closed
$52.70
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The Company’s segments include Commercial Operations and Research and Development. The firm is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. General medicines include inhalers for asthma and chronic obstructive pulmonary disease (COPD) with antibiotics. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development. The firm also engaged in ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody. The firm also owns HS235, a potential molecule for the treatment of pulmonary hypertension (PH).
Country

GB

CEO

Dame Emma Walmsley

IPO date

1972

Employees

66,841

ISIN

GB00BN7SWP63

Key stats

Open

$52.89

Volume

2.36M

Market cap

$106.50B

Prev. close

$52.47

Impl / hst vl

-

Open interest

$0.00

$52.31

Day’s Range

$53.08

$47.77

52W Range

$61.70

Valuation

61
Valuation score
Undervalued
P/E
13.60
P/S
2.42
P/B
4.44
Current ratio
0.79
Debt / Equity
0.87
ROE
35.78%
Gross margin
75.54%
Income growth
173.11%
FCF growth
-44.29

Jul

9

Dividends

The last payment date was Jul 9, 2026

Div. per Share

$0.62

Div. Yield

0.88%

Payout Ratio

-

Div. Growth YoY

-6.79%

Analysts estimates

Consensus rating
Hold

The average rating from top 13 analysts indicates that stock may significantly underperform the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$57.08
The top 22 analysts forecasts that 12-month price may increase by 8.31%, with a low of $39.21 and a high of $77.03
$39.21
Low
$57.08
Avg
$77.03
High
Current price

Earnings

Q1 ‘26 revenue
$10.25B
Q1 ‘26 net income
$2.33B
Revenue
Net income
Previous EPS
$0.62
Estimate EPS
$0.63
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply